Tag:

Gilead Sciences

Latest Headlines

Latest Headlines

Drug price increases hit record for Q2, with no sign of slowdown, analysts say

We've heard plenty of anecdotal reports about expensive drugs, from the long-running brouhaha over Gilead Sciences' hepatitis C drugs to the consternation about pricey new cancer meds. But occasionally, there's a broader view--and not surprisingly, that shows some impressive price inflation, too.

Ascletis plans China, Taiwan PhIII trials on chronic hep C therapies

China-based Ascletis Pharmaceuticals has notched up a first with plans for Phase III trials of danoprevir (ASC08) and ASC16 (PPI-668) to treat chronic hepatitis C in China and Taiwan. If successful, the trials could represent a milestone that could reach an estimated patient population of 30 million to 40 million, the highest worldwide.

Which Big Biotechs join Gilead in Fortune's fastest-growing pharma ranks?

The company at the top of Fortune's fastest-growing-in-pharma list is just the one you'd expect: Gilead Sciences, with its hep C-fueled leap into the industry's top 10 by revenue. And it's no surprise that the next two are Big Biotech companies, given the ascendance of biologic meds. But one Big Pharma--and only one--managed to crack the top 5.

After stalling for months, NHS England pledges £190M for new hep C treatments

Gilead Sciences and AbbVie are quick to tout the efficacy of their hep C meds. Now, those numbers have helped the drugmakers score a win in the U.K. as the country's National Health Service (NHS) will spend £190 million ($294 million) for new treatments for the disease, including AbbVie's interferon-free treatment and Gilead's blockbuster hep C therapies.

Booming Gilead is opening new labs, planning fresh hires in R&D blitz

Flush with a new, multibillion-dollar drug franchise, a booming Gilead is now hiring investigators for its fast-growing operations in Canada. The biotech is doubling down on its $100 million R&D investment in Alberta, Canada, with plans to expand on the new lab that opened this week at its Edmonton campus as it hires up to 170 more scientists for its R&D work.

Gilead Sciences plans $100M expansion of Edmonton plant

Gilead Sciences said it's investing an additional $100 million to expand its operations in Edmonton, Canada.  

GlobeImmune's Gilead-partnered hep B vaccine fails in Phase II

GlobeImmune's in-development vaccine for hepatitis B missed the mark in a Phase II trial, marring the value of a program licensed to Gilead Sciences.

Study: Gilead's Harvoni could save U.S. and Europe billions in worker productivity

Gilead Sciences has a new swath of research showing that investing in new hep C therapies could potentially save the U.S. and Europe billions of dollars in lost productivity.

33 indicted for selling BMS' Abilify, Novartis' Gleevec in massive diversion scheme

Federal authorities have rounded up nearly three dozen people indicted in a far-ranging scheme in which they allegedly sold $200 million worth of diverted drugs that included blockbusters like Bristol-Myers Squibb's antipsychotic Abilify, Gilead Sciences' HIV med Truvada and Novartis' cancer drug Gleevec.

UPDATED: AdverseEvents: New generation of hep C meds bests older therapies in side-effect reports

A new generation of hep C therapies could offer key safety advantages over older treatments, as a recent analysis by healthcare informatics firm AdverseEvents found that Gilead Sciences' Sovaldi and Harvoni were linked to fewer serious side effects in postmarketing data.